Dr. Michael Levy, M.D., PH.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (2004)
- Years since graduation
- 22
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 95
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2004Medical school: Baylor College of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MA license 277585 · MD license D64941
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Massachusetts General Hospital Boston, MA
- North Shore Medical Center - Salem, MA
- Wentworth-Douglass Hospital Dover, NH
- Martha's Vineyard Hospital Inc Oak Bluffs, MA
Medical groups
- Massachusetts General Physicians Organization Inc (3,558 clinicians)
- The General Hospital Corporation (1,267 clinicians)
- Martha's Vineyard Hospital Inc (155 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 95
- Services billed
- 173
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 43 | 33 |
| Established patient office or other outpatient visit, 40-54 minutes | 41 | 40 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Gabapentin Other prescribers in Boston, MA | 47 |
| Baclofen Other prescribers in Boston, MA | 42 |
| Pregabalin Other prescribers in Boston, MA | 41 |
| Privigen (immun glob g(igg)/pro/iga 0-50) | 38 |
| Enspryng (satralizumab-mwge) | 29 |
| Deferiprone | 29 |
| Ferriprox (deferiprone) | 25 |
| Sodium Chloride (0.9 % sodium chloride) Other prescribers in Boston, MA | 22 |
| Ferriprox (3 Times A Day) (deferiprone) | 21 |
| Mycophenolic Acid (mycophenolate sodium) | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 70 payments worth $84,839 in total to this clinician.
| UCB SA | $23,100 |
|---|---|
| UCB GmbH | $20,360 |
| Alexion Pharmaceuticals, Inc. | $14,104 |
| Tanabe Pharma Corporation | $8,701 |
| Amgen Inc. | $5,688 |
| E.r. Squibb & Sons, L.l.c. | $4,056 |
| Genentech, Inc. | $2,604 |
| Merck Sharp & Dohme LLC | $2,093 |
| Consulting Fee | $53,348 |
|---|---|
| Travel and Lodging | $29,603 |
| Food and Beverage | $1,828 |
| Education | $60.50 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| UCB SA Dec 19, 2025 | Consulting Fee | $14,300 |
| UCB SA Jan 17, 2025 | Consulting Fee Rystiggo · Neurology | $8,800 |
| Tanabe Pharma Corporation Oct 4, 2025 | Travel and Lodging travel to Chiba, Japan · in-kind | $7,789 |
| Amgen Inc. Apr 14, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $4,950 |
| UCB GmbH Nov 9, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Verona, Italy · in-kind | $4,928 |
| UCB GmbH Nov 9, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Verona, Italy · in-kind | $4,928 |
| UCB GmbH Nov 7, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $4,558 |
| UCB GmbH Nov 7, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $4,558 |
| Alexion Pharmaceuticals, Inc. May 12, 2025 | Consulting Fee | $4,438 |
| Alexion Pharmaceuticals, Inc. Dec 17, 2025 | Consulting Fee | $3,550 |
All 31 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| UCB SA Dec 19, 2025 | Consulting Fee | $14,300 |
| Alexion Pharmaceuticals, Inc. Dec 17, 2025 | Consulting Fee | $3,550 |
| Alexion Pharmaceuticals, Inc. Dec 17, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $3,550 |
| Genentech USA, Inc. Dec 9, 2025 | Consulting Fee | $825 |
| Alexion Pharmaceuticals, Inc. Dec 8, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $2,485 |
| Genentech, Inc. Nov 14, 2025 | Consulting Fee Ocrevus · Immunology | $1,269 |
| Genentech, Inc. Nov 14, 2025 | Consulting Fee Ocrevus · Immunology | $1,269 |
| UCB GmbH Nov 9, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Verona, Italy · in-kind | $4,928 |
| UCB GmbH Nov 9, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Verona, Italy · in-kind | $4,928 |
| UCB GmbH Nov 9, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Verona, Italy · in-kind | $237 |
| UCB GmbH Nov 9, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Verona, Italy · in-kind | $237 |
| UCB GmbH Nov 7, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $4,558 |
| UCB GmbH Nov 7, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $4,558 |
| UCB GmbH Nov 7, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $457 |
| UCB GmbH Nov 7, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $457 |
| Celgene Corporation Oct 23, 2025 | Travel and Lodging travel to Chicago, IL | $341 |
| Tanabe Pharma Corporation Oct 4, 2025 | Travel and Lodging travel to Chiba, Japan · in-kind | $7,789 |
| Tanabe Pharma Corporation Oct 4, 2025 | Travel and Lodging travel to Chiba, Japan · in-kind | $654 |
| Tanabe Pharma Corporation Oct 4, 2025 | Travel and Lodging travel to Chiba, Japan · in-kind | $222 |
| Tanabe Pharma Corporation Oct 4, 2025 | Travel and Lodging travel to Chiba, Japan · in-kind | $21.00 |
| E.r. Squibb & Sons, L.l.c. Jul 15, 2025 | Consulting Fee | $1,920 |
| Alexion Pharmaceuticals, Inc. May 12, 2025 | Consulting Fee | $4,438 |
| E.r. Squibb & Sons, L.l.c. Apr 25, 2025 | Consulting Fee | $1,920 |
| Amgen Inc. Apr 14, 2025 | Consulting Fee UPLIZNA · Inflammation/Rare Disease | $4,950 |
| F. Hoffmann-la Roche AG Apr 7, 2025 | Consulting Fee | $1,050 |
| Ipsen Pharma Sas Mar 27, 2025 | Consulting Fee Dysport · Neurology | $630 |
| Amgen Inc. Mar 17, 2025 | Education UPLIZNA · Inflammation/Rare Disease · in-kind | $60.50 |
| Merck Sharp & Dohme LLC Jan 20, 2025 | Consulting Fee | $2,093 |
| UCB SA Jan 17, 2025 | Consulting Fee Rystiggo · Neurology | $8,800 |
| E.r. Squibb & Sons, L.l.c. Jan 14, 2025 | Travel and Lodging travel to WIEN, Austria | $216 |
| F. Hoffmann-la Roche AG Jan 8, 2025 | Consulting Fee | $300 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 4 companies. The companies reported $1,189,520 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
UCB SA · Active, not recruiting · NCT05063162 - Satralizumab in MOG AD
Genentech, Inc. - Preference for Inebilizumab Infused at Home
Amgen Inc. - Satralizumab in NMOSD patients 100kg
Genentech, Inc. - A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Alexion Pharmaceuticals, Inc. - A Phase 2 3, Open label, Historical controlled, Single arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin 4 antibo…
Alexion Pharmaceuticals, Inc. - A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor T…
Alexion Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.